Redeye updates on EG7 post Q3-results which were better than expected, driven by strong profitability in Daybreak. While the company lowered its guidance for 2024, we have made limited changes to our estimates as we had already assumed that the target would be challenging to achieve. Nevertheless, the company looks set to end the year strongly with continued result improvement in Q4 2024.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/